Profile data is unavailable for this security.
About the company
Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on the development and commercialization of therapies to address unmet medical needs and improve the lives of patients. The Company’s commercial portfolio consist of three products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome (SMS) and PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Tradipitant, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.
- Revenue in USD (TTM)216.11m
- Net income in USD-220.47m
- Incorporated2002
- Employees533.00
- LocationVanda Pharmaceuticals IncSUITE 300E, 2200 PENNSYLVANIA AVE NWWASHINGTON 20037United StatesUSA
- Phone+1 (202) 734-3400
- Fax+1 (202) 296-1450
- Websitehttps://www.vandapharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Atea Pharmaceuticals Inc | 0.00 | -147.03m | 336.73m | 56.00 | -- | 1.07 | -- | -- | -1.78 | -1.78 | 0.00 | 4.04 | 0.00 | -- | -- | 0.00 | -35.26 | -9.87 | -37.29 | -11.45 | -- | -- | -- | -77.50 | -- | -- | 0.00 | -- | -- | -- | -23.85 | -- | -- | -- |
| Aclaris Therapeutics Inc | 15.74m | -141.68m | 345.62m | 64.00 | -- | 2.88 | -- | 21.96 | -1.38 | -1.38 | 0.136 | 1.11 | 0.088 | -- | 6.27 | 245,968.80 | -79.17 | -48.16 | -90.39 | -55.11 | 3.98 | 40.68 | -900.01 | -483.49 | -- | -- | 0.00 | -- | -40.09 | 34.67 | -49.26 | -- | 86.02 | -- |
| Adlai Nortye Ltd (ADR) | 0.00 | -42.59m | 350.92m | 123.00 | -- | 44.30 | -- | -- | -1.14 | -1.14 | 0.00 | 0.2147 | 0.00 | -- | -- | 0.00 | -47.40 | -- | -138.41 | -- | -- | -- | -- | -- | -- | -26.36 | 0.8491 | -- | -- | -- | 52.51 | -- | -- | -- |
| Aura Biosciences Inc | 0.00 | -106.47m | 353.71m | 106.00 | -- | 2.24 | -- | -- | -1.93 | -1.93 | 0.00 | 2.49 | 0.00 | -- | -- | 0.00 | -53.86 | -36.26 | -58.85 | -38.42 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.76 | -- | -10.82 | -- |
| Rocket Pharmaceuticals Inc | 0.00 | -240.91m | 353.89m | 299.00 | -- | 1.13 | -- | -- | -2.25 | -2.25 | 0.00 | 2.90 | 0.00 | -- | -- | 0.00 | -63.25 | -38.97 | -69.77 | -41.67 | -- | -- | -- | -- | -- | -- | 0.0635 | -- | -- | -- | -5.35 | -- | -24.10 | -- |
| Benitec Biopharma Inc | 0.00 | -46.30m | 355.57m | 19.00 | -- | 1.90 | -- | -- | -1.11 | -1.11 | 0.00 | 5.47 | 0.00 | -- | -- | 0.00 | -34.33 | -79.73 | -35.10 | -88.81 | -- | 88.41 | -- | -53,777.78 | -- | -- | 0.00 | -- | -- | -- | -69.50 | -- | -28.30 | -- |
| Vanda Pharmaceuticals Inc. | 216.11m | -220.47m | 359.97m | 533.00 | -- | 1.10 | -- | 1.67 | -3.74 | -3.74 | 3.67 | 5.54 | 0.3774 | 7.29 | 4.25 | 405,450.30 | -38.51 | -6.49 | -48.99 | -7.64 | 93.96 | 92.12 | -102.02 | -17.46 | 2.38 | -- | 0.0224 | -- | 8.72 | -2.73 | -1,066.53 | -- | -11.08 | -- |
| Bicycle Therapeutics PLC (ADR) | 28.34m | -250.66m | 363.49m | 305.00 | -- | 0.5872 | -- | 12.83 | -3.62 | -3.62 | 0.4094 | 8.92 | 0.0322 | -- | 0.4525 | 92,914.76 | -28.47 | -26.61 | -30.66 | -29.60 | -- | -- | -884.51 | -587.28 | -- | -- | 0.0015 | -- | 30.76 | 20.65 | 6.44 | -- | -4.50 | -- |
| Anavex Life Sciences Corp | 0.00 | -39.95m | 364.20m | 34.00 | -- | 2.88 | -- | -- | -0.4649 | -0.4649 | 0.00 | 1.37 | 0.00 | -- | -- | 0.00 | -31.08 | -33.08 | -33.63 | -36.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.85 | -- | -- | -- |
| Northwest Biotherapeutics Inc | 937.00k | -91.22m | 366.88m | 25.00 | -- | -- | -- | 391.55 | -0.0655 | -0.0655 | 0.0007 | -0.0627 | 0.0313 | -- | -- | 37,480.00 | -299.59 | -398.92 | -- | -- | -- | -- | -9,580.90 | -8,255.92 | -- | -6.69 | -- | -- | -28.47 | -10.53 | -32.34 | -- | 23.01 | -- |
| Rezolute Inc | 0.00 | -84.23m | 367.48m | 71.00 | -- | 2.87 | -- | -- | -0.9239 | -0.9239 | 0.00 | 1.34 | 0.00 | -- | -- | 0.00 | -67.21 | -47.11 | -73.08 | -49.55 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -8.70 | -- | -- | -- |
| NovaBridge Biosciences | 0.00 | -26.33m | 370.08m | 32.00 | -- | 1.43 | -- | -- | -0.3045 | -0.2827 | 0.00 | 2.25 | 0.00 | -- | -- | 0.00 | -10.32 | -26.21 | -10.92 | -30.19 | -- | -- | -- | -389.26 | -- | -- | 0.00 | -- | -100.00 | -- | 39.56 | -- | -51.41 | -- |
| Monopar Therapeutics Inc | 0.00 | -19.44m | 370.62m | 16.00 | -- | 2.61 | -- | -- | -3.44 | -3.44 | 0.00 | 21.25 | 0.00 | -- | -- | 0.00 | -25.88 | -52.66 | -26.53 | -59.31 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -85.50 | -- | -- | -- |
| Greenwich Lifesciences Inc | 0.00 | -19.48m | 371.99m | 4.00 | -- | 169.51 | -- | -- | -1.46 | -1.46 | 0.00 | 0.1584 | 0.00 | -- | -- | 0.00 | -404.39 | -49.65 | -543.43 | -51.94 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -77.57 | -- | -- | -- |
| Immix Biopharma Inc | 0.00 | -23.56m | 382.28m | 18.00 | -- | 29.30 | -- | -- | -0.7742 | -0.7742 | 0.00 | 0.2502 | 0.00 | -- | -- | 0.00 | -104.21 | -108.46 | -169.47 | -146.18 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.11 | -- | 176.33 | -- |
| Lineage Cell Therapeutics Inc | 10.82m | -67.66m | 382.34m | 70.00 | -- | 17.35 | -- | 35.35 | -0.2955 | -0.2955 | 0.0469 | 0.0957 | 0.1162 | -- | 40.66 | 154,514.30 | -72.50 | -20.81 | -81.52 | -24.54 | 97.84 | 90.99 | -624.16 | -331.61 | -- | -- | 0.004 | -- | 6.19 | 22.00 | 13.39 | -- | 5.13 | -- |
Data as of Feb 17 2026. Currency figures normalised to Vanda Pharmaceuticals Inc's reporting currency: US Dollar USD
42.60%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Dec 2025 | 5.37m | 9.09% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 3.38m | 5.72% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 3.28m | 5.55% |
| Acadian Asset Management LLCas of 31 Dec 2025 | 2.41m | 4.08% |
| Tang Capital Management LLCas of 30 Sep 2025 | 2.35m | 3.98% |
| Dimensional Fund Advisors LPas of 31 Dec 2025 | 2.04m | 3.46% |
| AIGH Capital Management LLCas of 31 Dec 2025 | 2.00m | 3.38% |
| Millennium Management LLCas of 31 Dec 2025 | 1.68m | 2.84% |
| Geode Capital Management LLCas of 31 Dec 2025 | 1.39m | 2.36% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 1.26m | 2.14% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
